SHSofia Hemrage

Sofia Hemrage

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Sofia Hemrage has a total of 37 co-authors. Here are the top co-authors by number of shared publications:

  • Colin Drummond

    Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK

    5 shared publications
  • Naina Shah

    Institute of Liver Studies King's College Hospital London UK

    5 shared publications
  • Paolo Deluca

    Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK

    5 shared publications
  • Stephen Parkin

    Department of Addictions, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK

    5 shared publications
  • Colin Drummond

    National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London

    4 shared publications
  • Eileen Brobbin

    National Addiction Centre, Institute of Psychiatry, Psychology and Neuroscience King's College London London UK

    4 shared publications

Latest Publications

  • Open Access

    Models of care for the management of alcohol use disorder in general hospital settings and transition to the community: a scoping review.

    by Julia M A Sinclair, Sofia Hemrage, Nicola J Kalk, Georgia Foote, Melinda King, Julia Morris, Seilin Uhm, Amy Kitajima, Paul S Haber, Thomas Phillips

    Early detection of alcohol use disorder (AUD) amongst people admitted to general hospitals offers an opportunity for early intervention and accesses to evidence-based care. However, current operational models for the management of AUD in these settings are poorly defined, limiting the ability to assess their impact on individual patient outcomes, treatment effectiveness, or healthcare system efficiency. This scoping review aims to identify and characterize existing models of AUD management within general hospitals. A scoping review approach was adopted, including relevant peer-reviewed publications between 1990 and 2025. Studies needed to report on ≥2 care components (systematic screening, brief interventions, medically assisted alcohol withdrawal, relapse prevention initiation, psychosocial interventions, transition to community, provision of training) to be included. Screening and data extraction were performed independently by at least reviewers. Fifty-one (n = 51) records were included, and four distinct models of care were identified (consultation liaison; screening, brief intervention, and referral to treatment; protocol implementation; supported diversion). Models varied in their clinical purpose, target population, and care delivery focus. Within each model, differences in aims, context, and implementation resulted in substantial heterogeneity. Consultation liaison models provided the most multifaceted care, with a specialist team providing clinical leadership, access to evidence-based interventions, transition to community services, and training of the wider workforce, but rarely described any wider systematic screening for AUD. A consistent observation across all identified models was the limited interface with mental health care, representing a critical gap in current AUD management within general hospitals.

  • Top Cited Papers
    Open Access

    Evidence-based consensus guidelines for the pharmacological management of substance dependence: Recommendations from the British Association for Psychopharmacology

    by Julia M. A. Sinclair, Nicola J. Kalk, Stephen J. Kaar, Roberta Agabio, Shalini Arunogiri, Adam Bisaga, Edward Chesney, Chris Daly, Jonathan Dewhurst, Tom P. Freeman, et al.

    The British Association for Psychopharmacology guidelines for the management of substance dependence focus primarily on the pharmacological aspects of treatment. A group of international experts from a wide range of disciplines reviewed the current evidence in their field, considered the strength of the evidence and discussed the clinical implications at a consensus meeting. The guidelines focus on the pharmacological management of dependence on alcohol, benzodiazepines, ‘z-drugs’, γ-hydroxybutyrate (GHB), gabapentinoids, opioids, nicotine, cannabis and synthetic cannabinoids, cocaine, amphetamine and methamphetamine, dissociative drugs and their analogues. They are based on the available evidence and make recommendations to aid clinical decision making, as well as highlighting the gaps in the current evidence-base.


  • Open Access

    Contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol‐related liver disease: Findings from a pilot randomized controlled trial

    by Sofia Hemrage, Nicola Kalk, Naina Shah, Stephen Parkin, Paolo Deluca, Colin Drummond

    Background: Alcohol‐related liver disease (ARLD) is a leading cause of preventable death and health inequalities. Evidence‐based interventions for comorbid alcohol use disorder (AUD) and ARLD remain limited, and only a small proportion of this clinical population engages with treatment. There is a need to improve patient outcomes by bridging this gap through novel, person‐centred interventions. Contingency management (CM) is a psychosocial intervention that involves gradual, increasing incentives upon the completion of treatment‐related goals, such as treatment attendance. This single‐centre, randomized pilot trial of voucher‐based CM was conducted to promote treatment engagement in comorbid AUD and ARLD.Methods: Thirty service users were recruited from an inpatient setting, offered integrated liver care (ILC) and allocated to ILC only or ILC + CM. Primary outcomes included feasibility criteria (recruitment, study retention post‐randomization, completeness of data and protocol fidelity). Secondary outcome data on engagement, alcohol intake, and liver function were also collected. Data were gathered at baseline, post‐ILC, and 12 weeks post‐ILC and analyzed through descriptive statistics.Results: The feasibility of the research was subject to challenges inherent to conducting applied health research in a real‐world clinical setting. The recruitment and retention rates were 73.20% and 36.70%, respectively. All participants received CM per protocol. An increasing trend in engagement was observed in the ILC + CM compared to ILC only (67% vs. 33%). A trending 76% reduction in alcohol intake and an overall improvement in liver outcomes were observed among participants engaging with the trial, with no significant differences between control and treatment groups.Conclusion: Overall, the CM intervention was feasible to deliver and appears promising in improving outcomes in individuals with comorbid AUD and ARLD. Aspects related to recruitment, study retention post‐randomization, and protocol fidelity need to be further adapted before proceeding with a definitive trial.


  • Open Access

    Voucher‐based contingency management to promote treatment engagement in comorbid alcohol use disorder and alcohol‐related liver disease: A pilot theory‐informed qualitative study with service users

    by Sofia Hemrage, Stephen Parkin, Nicola Kalk, Naina Shah, Paolo Deluca, Colin Drummond

    Background: Effective interventions for the management of alcohol‐related liver disease (ARLD) remain a gap in clinical practice, and patients' engagement with alcohol services is suboptimal. Based upon the principles of operant conditioning, contingency management (CM) is a psychosocial intervention th at involves gradual, increasing incentives upon completion of treatment‐related goals such as treatment attendance.Methods: A pilot feasibility trial was conducted with 30 adult patients recruited from an inpatient clinical setting. Consecutive sampling was used to recruit patients presenting comorbid alcohol use disorder (AUD) and ARLD. Participants were randomized to integrated liver care (ILC), receiving hepatology and AUD care, or ILC with a voucher‐based CM intervention (intervention arm). A longitudinal qualitative approach was adopted to explore anticipated (Stage 1) and experienced acceptability (Stage 2). The Theoretical Framework of Acceptability (TFA) guided semi‐structured in‐depth interviews and deductive analysis.Results: Thirty participants were enrolled in the pilot trial, and interviews were conducted with 24 participants at Stage 1 and seven at Stage 2. Over half of the cohort (54.2%, n = 13) presented decompensated liver disease, and an average of 179 units of alcohol were consumed per week. Overall positive views toward voucher‐based CM were noted, and explanatory data emerged across five TFA domains (intervention coherence, ethicality, self‐efficacy, perceived effectiveness, and affective attitude). The core aspects of the voucher‐based CM intervention matched participants' preferences and needs. Participants regarded CM as having a symbolic value and strengthening the therapeutic alliance with healthcare providers.Conclusion: The data support the scope of voucher‐based CM intervention to promote engagement with treatment services, and its potential to address the gaps in the care continuum in ARLD. The findings are of practical significance for developing person‐centered, tailored interventions for this clinical population. The outcomes of this investigation can inform decision‐making among stakeholders and healthcare providers and improve health outcomes for this clinical population.


  • Open Access

    Treatment engagement in comorbid alcohol use disorder and alcohol‐related liver disease: A qualitative exploration of barriers and facilitators with service users

    by Sofia Hemrage, Stephen Parkin, Nicola Kalk, Naina Shah, Paolo Deluca, Colin Drummond

    Background: Effective interventions to improve patient outcomes in comorbid alcohol use disorder (AUD) and alcohol‐related liver disease (ARLD) remain a clinical unmet need. While the choice of abstinence is the cornerstone for the prevention of disease progression and mortality, evidence suggests a suboptimal engagement with treatment supporting recovery. This qualitative investigation aims to understand barriers and facilitators to treatment as experienced by this clinical population by applying a multidimensional adherence model proposed by the World Health Organization.Methods: Twenty‐four participants with comorbid AUD and ARLD were recruited from an inpatient clinical setting. Data for this study were collected through semistructured, in‐depth interviews. Deductive analysis was organized by the Framework method, and theory‐driven themes were identified according to the multidimensional adherence model. This included factors across the social and economic, patient, condition, treatment, and healthcare system levels.Results: The findings in this study indicate systematic challenges in maintaining continuity between primary, secondary, and community care. Aspects related to social and economic context, treatment, and healthcare systems were found to hinder engagement. Identified facilitators to engagement included the participatory role of family, shared lived experience of addiction/recovery, and therapeutic alliance with healthcare providers.Conclusion: The understanding of these barriers and facilitators from a service user's perspective can bridge the treatment gap for this clinical population. This can provide an opportunity for the implementation of effective interventions and inform the development of policies promoting accessible care. Government and public health bodies have fundamental roles in shifting treatment paradigms in comorbid AUD and ARLD.


  • Open Access

    Inequity in clinical research access for service users presenting comorbidity within alcohol treatment settings: findings from a focused ethnographic study

    by Sofia Hemrage, Stephen Parkin, Nicola J. Kalk, Naina Shah, Paolo Deluca, Colin Drummond

    Background: While healthcare policy has fostered implementation strategies to improve inclusion and access of under-served groups to clinical care, systemic and structural elements still disproportionately prevent service users from accessing research opportunities embedded within clinical settings. This contributes to the widening of health inequalities, as the absence of representativeness prevents the applicability and effectiveness of evidence-based interventions in under-served clinical populations. The present study aims to identify the individual (micro), organisational (meso) and structural (macro) barriers to clinical research access in patients with comorbid alcohol use disorder and alcohol-related liver disease. Methods: A focused ethnography approach was employed to explore the challenges experienced by patients in the access to and implementation of research processes within clinical settings. Data were collected through an iterative-inductive approach, using field notes and patient interview transcripts. The framework method was utilised for data analysis, and themes were identified at the micro, meso and macro levels. Results: At the micro-level, alcohol-related barriers included encephalopathy and acute withdrawal symptoms. Alcohol-unrelated barriers also shaped the engagement of service users in research. At the meso-level, staff and resource pressures, as well as familiarity with clinical and research facilities were noted as influencing intervention delivery and study retention. At the wider, macro-level, circumstances including the ‘cost of living crisis’ and national industrial action within healthcare settings had an impact on research processes. The findings emphasise a ‘domino effect’ across all levels, demonstrating an interplay between individual, organisational and structural elements influencing access to clinical research. Conclusions: A combination of individual, organisational and structural barriers, exacerbated by the COVID-19 pandemic, and the socioeconomic landscape in which the study was conducted further contributed to the unequal access of under-served groups to clinical research participation. For patients with comorbid alcohol use disorder and alcohol-related liver disease, limited access to research further contributes towards a gap in effective evidence-based treatment, exacerbating health inequalities in this clinical population.


  • Open Access

    Inequity in clinical research access for service users presenting comorbidity within alcohol treatment settings: findings from a focused ethnographic study

    by Sofia Hemrage, Stephen Parkin, Nicola J Kalk, Naina Shah, Paolo Deluca, Colin Drummond

    Background While healthcare policy has fostered implementation strategies to improve inclusion and access of under-served groups to clinical care, systemic and structural factors still disproportionately prevent service users from accessing research opportunities embedded within clinical settings. This contributes to the widening of health inequalities, as the absence of representativeness prevents the applicability and effectiveness of evidence-based interventions in under-served clinical populations. The present study aims to identify the individual (micro), organisational (meso) and structural (macro) barriers to clinical research access in patients with comorbid alcohol use disorder and alcohol-related liver disease. Methods A focused ethnography approach was employed to explore the challenges experienced by patients in the access to and implementation of research processes within clinical settings. Data were collected through an iterative-inductive approach, using field notes and patient interview transcripts. The framework method was utilised for data analysis, and themes were identified at the micro, meso and macro levels. Results At the micro-level, alcohol-related barriers included encephalopathy and acute withdrawal symptoms. Alcohol-unrelated barriers also shaped the engagement of service users in research. At the meso-level, staff and resource pressures, as well as familiarity with clinical and research facilities were noted as influencing intervention delivery and study retention. At the wider, macro-level, circumstances including the ‘cost of living crisis’ and national industrial action within healthcare settings had an impact on research processes. The findings emphasise a ‘domino effect’ across all levels, demonstrating an interplay between individual, organisational and structural factors influencing access to clinical research. Conclusions A combination of individual, organisational and structural factors, exacerbated by the COVID-19 pandemic, and the socioeconomic landscape in which the study was conducted further contributed to the unequal access of under-served groups to clinical research participation. For patients with comorbid alcohol use disorder and alcohol-related liver disease, limited access to research further contributes towards a gap in effective evidence-based treatment, exacerbating health inequalities in this clinical population.

  • Open Access

    Efficacy of psychosocial interventions to reduce alcohol use in comorbid alcohol use disorder and alcohol-related liver disease: a systematic review of randomized controlled trials

    by Sofia Hemrage, Eileen Brobbin, Paolo Deluca, Colin Drummond

    This systematic review (PROSPERO CRD42021234598) fills a gap in the literature by assessing the efficacy of psychosocial interventions in patients with alcohol use disorder and alcohol-related liver disease (ARLD), focusing on drinking reduction and abstinence as intervention goals. A systematic search for randomized controlled trials (RCTs) was conducted across various databases. Study screening and data extraction were conducted independently by two reviewers. The data were presented through narrative synthesis. Primary outcomes were alcohol reduction and abstinence at the longest follow-up. Ten RCTs were included, evaluating interventions such as cognitive behavioral therapy (CBT), motivational enhancement therapy (MET), motivational interviewing, or peer support. The total population included 1519 participants. Four studies included a combination of more than one intervention, and two trialed an integrated approach, including medical and psychosocial management. A significant reduction was observed with MET, while abstinence was observed with peer support, MET, and CBT/MET within integrated treatment. The overall certainty of the evidence was moderate. Six studies presented a low risk of bias, one had some concerns, and three were high risk. The findings highlight the potential of psychosocial interventions, with MET being repeatedly associated with improved outcomes. Integrated treatment also demonstrated a promising role in ARLD. Future research should head toward improving the robustness and quality of the evidence. It should also aim to further tailor and trial new psychosocial interventions on this specific clinical population. This will enhance the translation of the evidence into real-world settings.


  • Open Access

    Acceptability and feasibility of wearable transdermal alcohol sensors: A systematic review (Preprint)

    by Eileen Brobbin, Paolo Deluca, Sofia Hemrage, Colin Drummond

    BACKGROUND Transdermal alcohol sensors (TAS) have the potential to be used to monitor alcohol consumption objectively and continuously. These devices can provide real-time feedback to the user, researcher or health professional and measure alcohol consumption and peaks of use, addressing some of the limits of self-reported data. OBJECTIVE This systematic review aims to evaluate the acceptability and feasibility of the currently available devices. METHODS A systematic search was conducted of the CINAHL, EMBASE, Google Scholar, MEDLINE, PsycINFO, PubMed and Scopus bibliographic databases in February 2021. Two members of the study team independently screened studies for inclusion, extracted data and assessed the risk of bias. The study’s methodological quality was appraised using the Mixed Methods Appraisal Tool. The primary outcome was TAS acceptability. The second outcome was feasibility. The data is presented as a narrative synthesis. RESULTS We identified and analysed 22 studies. Study designs included: laboratory and ambulatory-based studies, mixed designs, randomised controlled trials and focus groups and the length the device was worn ranged from days to weeks. While views on TAS were generally positive with high compliance, some factors were indicated as potential barriers and suggestions to overcome these. CONCLUSIONS There is a lack of research investigating the acceptability and feasibility of TAS devices as a tool to monitor alcohol consumption in clinical and non-clinical populations. While preliminary evidence suggests their potential in short-term, laboratory-based studies with volunteers, more research is needed to establish long-term, daily use with other populations, specifically clinical and within the criminal justice system.